Axsome Therapeutics Inc
(STU:19X)
€
81.28
-1.42 (-1.74%)
Market Cap: 3.94 Bil
Enterprise Value: 3.83 Bil
PE Ratio: 0
PB Ratio: 40.50
GF Score: 36/100 Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022 / 03:40PM GMT
Release Date Price:
€59.74
(-1.29%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Thanks, everyone, for joining. This is a fireside chat with Axsome Therapeutics. Let me read a brief disclosure statement before we get started. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. My name is Vikram Purohit. I'm one of the biotech analysts with the research team. Happy to have with me Herriot Tabuteau, CEO; and Mark Jacobson, COO of Axsome. Thanks for joining us.
Herriot Tabuteau
Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President
Thank you.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
So before we get into any specifics around pipeline Auvelity et cetera. Herriot, do you want to just level set for the audience and just provide a recap of some of the key milestones Axsome through work to do
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot